Mendus - About the company
Mendus is a funded company based in Stockholm (Sweden), founded in 2002. It operates as a Developer of cell-based therapies for cancer treatment. The company has 3424 active competitors, including 1139 funded and 799 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of cell-based therapies for cancer treatment. It offers allogeneic dendritic cell-based medicine, including Vididencel for acute myeloid leukemia, and ovarian cancer, and Ilixadencel for solid tumors.
- Website
- mendus.com
- Social
- Email ID
- *****@mendus.com
- Phone Number
- +46 **********
Key Metrics
Founded Year
2002
Location
Stockholm, Sweden
Stage
Funding Raised
Investors
Ranked
1930th among 3424 active competitors
Employee Count
24 as on Aug 31, 2026
Investment & Acquisitions
Similar Companies
Sign up to download Mendus' company profile
Mendus's funding and investors
Mendus is a funded company. Mendus has 1 institutional investor.
View details of Mendus's funding rounds and investors
Mendus' founders and board of directors
Founder? Claim ProfileMendus' employee count trend
Mendus has 24 employees as of Aug 26. Here is Mendus's employee count trend over the years:
Uncover Mendus' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mendus's Competitors and alternates
Top competitors of Mendus include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Mendus, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
1930th | Developer of cell-based therapies for cancer treatment | - | 29/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Mendus's competitors? Click here to see the top ones
Mendus's Investments and acquisitions
Mendus has acquired DCprime. Mendus has not made any investments as of now.Reports related to Mendus
Here is the latest report on Mendus's sector:
News related to Mendus
Filter this list•
The exercise period for warrants of series TO3 begins todayGlobeNewswire•Mar 15, 2024•Mendus, Flerie
•
•
•
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AMLGlobeNewswire•Dec 06, 2023•Mendus, Allg
•
•
Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23GlobeNewswire•Sep 21, 2023•Mendus
•
FDA grants fast track designation to leukemia, lymphoma and endometrial cancer therapiesHealio•Sep 19, 2023•Mendus
•
Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)GlobeNewswire•Sep 08, 2023•Mendus
•
Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory BoardGlobeNewswire•Jun 20, 2023•Mendus
•
Mendus receives ATMP certificate from European Medicines Agency supporting its lead pipeline program vididencelGlobeNewswire•Jun 19, 2023•Mendus
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Mendus
Explore our recently published companies
- IndiAccess - India based, Unfunded company
- Marnitz & Associates Insurance - Lexington based, 1984 founded, Unfunded company
- Black Market Salsa - Albuquerque based, 2014 founded, Unfunded company
- Dundas 427 Automotive - Canada based, 1998 founded, Unfunded company
- Contact Festival Munich - Munich based, Unfunded company
- AV Home Improvement - United States based, Unfunded company
